Metuchen Must Correct ED Drug Ads For Adult Sites After US FDA Warning Letter
Executive Summary
Promotional campaign for Stendra (avanafil) included "adult sites" as well as the American College of Cardiology's patient-focused magazine; statements that FDA found problematic in the various ads include "get hard and stay hard" and calling the product a "next generation" PDE-5 inhibitor.
You may also be interested in...
YouTube Video Suggesting Livalo Is Safer Than Other Statins Is Dinged By US FDA
Kowa Pharmaceuticals' patient testimonials implying switch from statins to Livalo will reduce drug side effects are misleading, untitled letter says.
Warning Letter: New Sponsor, Same Violative Promotional Practices For Insomnia Drug Doral
An OPDP warning letter hits Galt Pharmaceuticals for misbranding its insomnia drug Doral with similar to concerns to those outlined in a 2014 untitled letter to the then-sponsor Sciecure.
US FTC Calls Out Personal Injury Rx Ads As Potentially Misleading
The US Federal Trade Commission says the ads may be causing patients to stop taking medications, asks that they include scientifically sound information and be careful using scare tactics.